全文获取类型
收费全文 | 55578篇 |
免费 | 3480篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 529篇 |
儿科学 | 2296篇 |
妇产科学 | 1514篇 |
基础医学 | 6945篇 |
口腔科学 | 539篇 |
临床医学 | 8552篇 |
内科学 | 9519篇 |
皮肤病学 | 756篇 |
神经病学 | 5329篇 |
特种医学 | 974篇 |
外科学 | 4603篇 |
综合类 | 591篇 |
一般理论 | 109篇 |
预防医学 | 7766篇 |
眼科学 | 760篇 |
药学 | 3632篇 |
中国医学 | 61篇 |
肿瘤学 | 4693篇 |
出版年
2023年 | 290篇 |
2022年 | 431篇 |
2021年 | 1016篇 |
2020年 | 693篇 |
2019年 | 1050篇 |
2018年 | 1202篇 |
2017年 | 977篇 |
2016年 | 1058篇 |
2015年 | 1237篇 |
2014年 | 1711篇 |
2013年 | 2728篇 |
2012年 | 3929篇 |
2011年 | 4240篇 |
2010年 | 2356篇 |
2009年 | 2127篇 |
2008年 | 3831篇 |
2007年 | 4075篇 |
2006年 | 3927篇 |
2005年 | 4068篇 |
2004年 | 3863篇 |
2003年 | 3636篇 |
2002年 | 3351篇 |
2001年 | 469篇 |
2000年 | 343篇 |
1999年 | 470篇 |
1998年 | 685篇 |
1997年 | 608篇 |
1996年 | 480篇 |
1995年 | 481篇 |
1994年 | 425篇 |
1993年 | 338篇 |
1992年 | 244篇 |
1991年 | 208篇 |
1990年 | 185篇 |
1989年 | 198篇 |
1988年 | 185篇 |
1987年 | 170篇 |
1986年 | 164篇 |
1985年 | 163篇 |
1984年 | 187篇 |
1983年 | 170篇 |
1982年 | 215篇 |
1981年 | 207篇 |
1980年 | 155篇 |
1979年 | 95篇 |
1978年 | 112篇 |
1977年 | 52篇 |
1976年 | 57篇 |
1975年 | 45篇 |
1974年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients 总被引:4,自引:0,他引:4
Gil Leibowitz Anat Tsur Susan D. Chayen Mohammad Salameh Itamar Raz Erol Cerasi & David J. Gross 《Clinical endocrinology》1996,44(6):717-722
OBJECTIVE Autonomous cortisol secretion without clinical stigmata of Cushing's syndrome (CS) has been recently recognized and termed pre-clinical or sub-clinical CS. The common assumption is that CS is an extremely rare cause of uncontrolled diabetes; however, the prevalence of this entity has not been studied. We assessed the prevalence of pre-clinical CS among obese patients with uncontrolled diabetes. PATIENTS AND DESIGN (1) In a retrospective analysis, the medical records of 63 patients with endogenous CS were reviewed. (2) In a cross-sectional study, 90 obese patients (BMI >25 kg/m2) followed in a University Hospital and the local Health Fund endocrine and diabetes clinics, with poorly controlled diabetes (glycosylated haemoglobin >9%), underwent an overnight 1 mg dexamethasone suppression. In patients with non-suppressible cortisol levels (>140 nmol/l), Liddle's 2 and 8 mg dexamethasone suppression tests and imaging studies were performed. MEASUREMENTS The prevalence of poorly controlled diabetes, the major presenting symptom of CS, was assessed in the retrospective analysis. The prevalence of ‘true’ CS and the false positive rate in the overnight dexamethasone suppression test were calculated. The endocrine evaluation of the patients with pre-clinical CS and the effects of surgical cure on glycaemic control are described. RESULTS In the retrospective analysis, 11 (17.5%) had diabetes and 2 (3.2%) lacked the classic physical characteristics of the syndrome. In the cross-sectional study, 4 patients failed to suppress plasma cortisol (<140 nmol/l). In one patient the diagnosis of CS was not confirmed by a standard Liddle’s test and was therefore considered false positive. In the other 3, the diagnosis of CS was confirmed (prevalence of 3.3%, 95% confidence interval 1–9%). In all other patients the overnight cortisol suppression test was normal (cortisol level 47.3 ± 2.5 nmol/l (mean ± SEM)). After surgical treatment of CS, glycaemic control was markedly improved in all 5 patients (2 from retrospective and 3 from cross-sectional studies). CONCLUSIONS The prevalence of pre-clinical Cushing's syndrome in obese patients with poorly controlled diabetes appears to be considerably higher than previously believed. The overnight dexamethasone suppression test proved to be a simple, sensitive and highly specific screening test for Cushing's syndrome despite the presence of obesity and hyperglycaemia. 相似文献
62.
A New York court recently struck down state Office of Mental Health regulations governing research involving subjects with impaired decisionmaking capacity. The court held that neither incapacitated adults nor minors could participate in any research protocol that contained a nontherapeutic element, irrespective of possible benefits to the subject or the importance of the knowledge to be gained. Although the decision rested on a technical point of law and dealt only with psychiatric research, the court's holding has significantly broader implications. 相似文献
63.
Susan Pelke RN David Easa MD 《Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG》1997,26(3):279-285
The clinical research coordinator plays a crucial role in organizing a site's participation in the expanding arena of multicenter medical and pharmacologic clinical trials. This summary clarifies the role of the clinical research coordinator for inexperienced staff members assuming these responsibilities and outlines planning procedures leading to successful implementation. Emphasis is placed on establishing an interdependent relationship with the principal investigator, careful protocol assessment, team building, and staff feedback. Useful tools such as study manuals and physicians' study orders are described. 相似文献
64.
65.
Perry Guaglianone Kenneth Chan Eduardo DelaFlor-Weiss Rosemarie Hanisch Susan Jeffers Desh Sharma Franco Muggia 《Investigational new drugs》1994,12(2):103-110
Summary We have completed a phase I and pharmacology study of liposomally-encapsulated daunorubicin (DaunoXome). Of 32 patients entered, 30 were evaluable. No toxicity was encountered at the initial doseescalation steps from 10 to 60 mg/m2. At 80 mg/m2, two patients manifested grade 2 neutropenia. At least grade 3 neutropenia occurred in all patients receiving 120 mg/m2. Alopecia and subjective intolerance were mild. Cardiotoxicity was not observed except for an episode of arrhythmia in a patient with lung cancer and prior radiation. Only one minor objective response was observed in this population of refractory solid tumors. Pharmacokinetics differed from those of the free drug with no detection of daunorubicinol. We recommend future phase II studies with a dose of 100 mg/m2 in previously treated and 120 mg/m2 of DaunoXome in previously untreated patients with solid tumors.EDW is supported in part by ACS award 92-14-1 相似文献
66.
S. S. Kerwar Susan C. Ridge M. Jane Landes Joseph C. Nolan Arnold L. Oronsky 《Inflammation research》1994,43(3-4):206-210
Rabbit inflamed synovial tissue grown in culture synthesizes a factor that induces collagenase synthesis in chondrocytes and in cartilage. Synthesis of this factor by the synovial tissue is inhibited by cycloheximide but not by indomethacin. The factor has an apparent molecular weight of 30,000, is stable to heat and to trypsin treatment but is inactivated by acid. Induction of collagenase synthesis in chondrocytes occurs after a lag period of 6 hours. 相似文献
67.
William V. Giannobile Rafaél A Hernandez Richard D. Finkelman Susan Ryarr Christopher P. Kiritsy Mark D'Andrea Samuel E. Lynch 《Journal of periodontal research》1996,31(5):301-312
Platelet-derived growth factor (PDGF) and insulin-like growth factor I (IGF-I) in combination have previously been shown to enhance periodontal regeneration. The objective of this study was to further characterize the biological effects of this combination of growth factors in non-human primates and compare the effects to those of each growth factor individually. Ligature-induced periodontitis was initiated in 10 cynomolgus monkeys. After periodontal lesions were established, surgery was performed, and either a methylcellulose gel vehicle or vehicle containing 10 μg each of either PDGF-BB, IGF-I or both PDGF-BB and IGF-I was applied to exposed root surfaces. Biopsies were taken 4 and 12 wk after treatment and the extent of periodontal regeneration was assessed by histomorphometry. At both 4 and 12 wk vehicle-treated lesions generally revealed minimal osseous defect fill (ODF) (8.5±2.1% and 14.5±5.7%, respectively) and new attachment (NA) (34.1±5.2% and 26.6±10.5%, respectively). IGF-I treatment did not significantly alter healing compared to vehicle in any parameter at both 4 and 12 wk. PDGFBB-treated sites exhibited significant (p<0.05) regeneration of NA (69.6±12.0%) at 12 wk; trends for PDGF-BB treatment effect were also observed in other parameters at 4 and 12 wk. although these increases were not statistically significant. Treatment with PDGF-BB/IGF-I resulted in 21.6±5.1 % and 42.5±8.3% ODF at 4 and 12 wk, respectively, and 64.1±7.7% and 74.6±7.4% NA at 4 and 12 wk, respectively (all significantly greater than vehicle, p<0.05). The results from this study demonstrated that: 1) IGF-1 alone at the dose tested did not significantly alter periodontal wound healing; 2) PDGF-BB alone significantly stimulated NA, with trends of effect on other parameters; and 3) the PDGF-BB/IGF-I combination resulted in significant increases in NA and ODF above vehicle at both 4 and 12 wk. 相似文献
68.
69.
70.
Tugba Yavuzsen Mellar P Davis Declan Walsh Susan LeGrand Ruth Lagman 《Journal of clinical oncology》2005,23(33):8500-8511
PURPOSE: We systematically assessed the efficacy and safety of appetite stimulants in the management of cancer-related anorexia. Literature databases were searched for randomized controlled trials of appetite stimulants in the treatment of cancer anorexia. MATERIALS AND METHODS: Studies were graded according to quality. Fifty-five studies met inclusion criteria. RESULTS: Only two drugs have evidence to support their use for anorexia (progestins and corticosteroids). There is strong evidence against the use of hydrazine sulfate. The outcomes of these trials have been mixed and patient population heterogeneous. CONCLUSION: The optimal dose, time to start, and duration of treatment for many appetite stimulants for cancer anorexia is still unknown. A more systematic approach to research methodology with universal outcome measure and prospective randomized studies are need. Combination regimens are needed but this cannot at the present time be supported by the data presented. 相似文献